Jazz Pharmaceuticals’ (JAZZ) Overweight Rating Reaffirmed at Piper Sandler
Piper Sandler reaffirmed their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report ...
Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab
Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates. I continue to see Jazz stock as a valuation ...
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 Sales
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.5% ...
FiercePharma3d
Jazz 'active and looking' at M&A deals of 'various sizes' as it wraps up Epidiolex patent fights: execs
Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought ...
Jazz Pharmaceuticals price target raised to $200 from $190 at Barclays
Barclays analyst Balaji Prasad raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $200 from $190 and keeps an Overweight rating ...
StockStory.org on MSN5d
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow after the bell. Here’s what to look ...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by New York State Common Retirement Fund
New York State Common Retirement Fund lessened its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) ...
Truist Financial Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)
Truist Financial analyst Joon Lee maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today. The company’s shares closed ...
Morningstar3d
Strong Uptake of Xywav and Epidiolex Drive Growth for Jazz Pharmaceuticals
Jazz Pharmaceuticals added its leading drug, Xyrem, to its portfolio in 2005 with the acquisition of Orphan Medical for about $123 million. This was a great price for the then newly approved drug ...
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2024 and ...
Jazz Pharmaceuticals plc Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
It's been a good week for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shareholders, because the company has just released its latest yearly results, and the shares gained 4.8% to US$143. The result was ...